Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703634 | 0.77 | RXFP1 (0.45) | KDR | |
| SCHEMBL7229531 | 0.74 | KDR (0.57) | KDR | |
| SCHEMBL6704628 | 0.73 | KDR (0.49) | KDR | |
| SCHEMBL6705038 | 0.72 | KDR (0.48) | KDR | |
| SCHEMBL6701891 | 0.71 | KDR (0.45) | KDR | |
| SCHEMBL7237669 | 0.71 | KDR (0.59) | KDR | |
| SCHEMBL3439331 | 0.70 | KDM4E (0.35) | TP53 | |
| SCHEMBL31575349 | 0.70 | KDM4E (0.35) | TP53 | |
| SCHEMBL5741877 | 0.69 | KDR (0.61) | KDR | |
| SCHEMBL25786936 | 0.67 | CYP1A2 (0.35) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235867-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2004-11-25 | — | — | US | claimed |
| WO-2003009852-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-06 | — | — | WO | claimed |
| US-20040235867-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2004-11-25 | — | — | US | disclosed |
| WO-2003009852-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235867-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885TP53 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.